查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466697

抗體契約製造市場：按抗體類型、來源、服務和最終用戶分類 - 2024-2030 年全球預測

Antibodies Contract Manufacturing Market by Antibody Type (Monoclonal Antibodies, Polyclonal Antibodies), Source (Mammalian, Microbial), Services, End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年抗體契約製造市場規模為163.4億美元，預計2024年將達180.4億美元，2030年將達335.6億美元，複合年成長率為10.82%。

抗體契約製造涉及將抗體生產和精製過程外包給專業公司。這種方法允許生物技術和製藥公司利用外部專業知識和先進設備來生產單株、多株抗體和重組抗體，而無需對基礎設施進行大量資本投資。抗體契約製造服務通常涵蓋廣泛的流程，包括細胞株開發、上游和下游加工、精製和最終製劑。抗體藥物在癌症、自體免疫疾病和感染疾病等慢性疾病的治療中變得越來越重要，增加了對專業製造服務的需求。對創新抗體療法的監管支持增加，加上生技藥品核准的簡化，正在推動與受託製造廠商(CMO) 的合作。智慧財產權問題以及與抗體契約製造相關的品質和合規風險不斷上升正在限制市場成長。生物加工、基因工程和高通量篩檢的技術進步正在加速新型抗體的開發並創造市場成長機會。

主要市場統計
基準年[2023] 163.4億美元
預測年份 [2024] 180.4億美元
預測年份 [2030] 335.6億美元
複合年成長率（%） 10.82%

抗體類型 由於單株抗體的均一性、特異性和大規模生產能力，對單株抗體的需求不斷增加。

單株抗體是針對特定抗原的抗體的相同副本。它們由單一克隆細胞或細胞株產生，具有親和性，僅與相同表位結合。在契約製造中，單株抗體是使用融合瘤開發、重組 DNA 和噬菌體展示等先進技術生產的。這些抗體有廣泛的應用，包括診斷、治療（針對癌症、自體免疫疾病和感染疾病等疾病）和研究。它們的均勻性、特異性和大量生產的能力使它們成為醫學和生物學領域的寶貴工具。多株抗體由不同 B 細胞克隆產生的混合抗體分子群組成。多株抗體可辨識並結合單一抗原上的多個表位。由於這種多樣性，多株抗體常用於免疫沉澱分析法和螢光方法中檢測各種抗原。生產涉及用抗原免疫合適的哺乳動物，例如兔子、山羊或小鼠。動物的免疫系統產生多種針對抗原的抗體，並且可以從血清中回收抗體。多株抗體因其高靈敏度和捕獲天然構象蛋白質的能力而備受讚譽，但批次間的變異性是其生產和使用中的一個重要考慮因素。

最終用戶：抗體契約製造擴大被生物技術和製藥公司採用，以利用抗體生產和精製方面的專業知識。

學術和研究機構是抗體契約製造市場最終用戶的重要組成部分。這些機構將先進的抗體開發服務用於各種研究目的，專注於闡明疾病機制、發現新的治療標靶和開發新型診斷工具。與受託製造廠商(CMO) 合作，無需對基礎設施進行大量投資，即可獲得尖端技術和專業知識，從而加快科學發現和創新的步伐。生技和製藥公司，從新新興企業到老字型大小企業，都嚴重依賴抗體契約製造服務來實現各種應用，包括開發治療性抗體和製造診斷試劑。這些公司通常專注於特定的治療領域或新穎的生物技術方法，需要高度專業、可擴展且具成本效益的抗體製造解決方案。受託製造合作夥伴關係使生物技術公司能夠應對複雜的監管環境，管理與生物製藥產品開發週期相關的風險，並加快創新的上市時間。透過與 CMO 合作，製藥和生物技術公司可以利用我們在抗體生產和精製的專業知識來最佳化製造流程並確保產品品質並符合全球監管標準。

區域洞察

美洲是全球市場格局中高度開拓的地區。該地區擁有強大的生物製藥研究、高額的醫療保健支出以及完善的法規環境。美國擁有多個重要的合約受託製造廠商(CMO)，提供從早期開發到大規模製造的廣泛服務。加拿大和巴西在這一領域也出現了成長，但美國在市場規模和技術進步方面繼續處於領先地位。生物技術投資的增加、生物相似藥需求的成長以及醫療保健基礎設施的改善為亞太地區抗體契約製造市場注入了活力。中國、韓國和印度等國家處於領先地位，政府實施了有利於生物技術進步的政策。尤其是中國，由於患者數量眾多以及生物技術產業的發展，CMO和合約開發與受託製造廠商（CDMO）的建立迅速增加。該地區的產品具有成本競爭力，加上品質標準的提高，使其成為外包抗體生產的有吸引力的地點。 EMEA（歐洲、中東和非洲）地區在抗體契約製造市場擁有強大的影響力，其中歐洲因其高度發展的生物製藥產業而處於領先地位。德國、英國和瑞士等國家以其複雜的生物技術生態系統而聞名，其中包括成熟的生物技術公司和新興的生物技術公司。嚴格的監管標準的存在確保了高品質的製造流程和產量。隨著對醫療基礎設施的投資和對生物技術研究興趣的增加，中東和非洲正逐漸迎頭趕上。

FPNV定位矩陣

FPNV定位矩陣對於評估抗體契約製造市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對抗體契約製造市場中供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.抗體契約製造市場的市場規模與預測是多少？

2.抗體契約製造市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3.抗體契約製造市場的技術趨勢和法規結構是什麼？

4.抗體契約製造市場主要廠商的市場佔有率是多少？

5.進入抗體契約製造市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 生物製藥療法的開發和商業化的需求
      • 對治療慢性疾病的先進抗體的需求不斷成長
      • 對個人化醫療的興趣日益濃厚
    • 抑制因素
      • 對生技藥品開發和製造的擔憂
    • 機會
      • 增加生物製藥管道並擴大契約製造服務
      • 增加全球抗體生產的研發預算
    • 任務
      • 雙/多特異性抗體形式的複雜性
  • 市場區隔分析
    • 抗體類型：單株抗體因其同質性、特異性和大規模生產能力而受到很高的需求。
    • 最終用戶：抗體契約製造擴大被生物技術和製藥公司採用，以利用他們在抗體生產和精製方面的專業知識。
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章 按抗體類型分類的抗體契約製造市場

  • 單株抗體
  • 多株抗體

第7章 抗體契約製造市場：依來源分類

  • 哺乳動物的
  • 微生物

第8章抗體契約製造市場：依服務分類

  • 分析開發和品管
  • 細胞株開發
  • 製程開發

第9章 抗體契約製造市場：依最終用戶分類

  • 學術研究機構
  • 生物技術和製藥公司

第10章 北美和南美抗體契約製造市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太抗體契約製造市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲的抗體契約製造市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 三星生物製品公司與 LEGOChem Biosciences 結成策略聯盟，加速固態腫瘤治療 ADC 創新
    • Aragen 在班加羅爾工廠投資 3,000 萬美元，以加強生物製藥生產能力
    • KBI Biopharma 推出 SUREmAb，單株抗體開發與加速製造解決方案
  • 戰略分析和建議

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-742BD517AE6B

[198 Pages Report] The Antibodies Contract Manufacturing Market size was estimated at USD 16.34 billion in 2023 and expected to reach USD 18.04 billion in 2024, at a CAGR 10.82% to reach USD 33.56 billion by 2030.

Antibodies contract manufacturing includes the outsourcing of antibody production and purification processes to specialized service providers. This approach allows biotechnology and pharmaceutical companies to leverage external expertise and advanced facilities for the production of monoclonal, polyclonal, and recombinant antibodies without the need for significant capital investments in infrastructure. Antibodies contract manufacturing services typically cover a broad spectrum of processes, including cell line development, upstream and downstream processing, purification, and final formulation. The growing emphasis on antibody-based drugs in the treatment of chronic diseases such as cancer, autoimmune diseases, and infectious diseases significantly fuels the need for specialized manufacturing services. Increasing regulatory support for innovative therapeutic antibodies, combined with streamlined approvals for biologics, promotes partnerships with contract manufacturing organizations (CMOs). Intellectual property concerns with rising quality and compliance risks associated with antibody contract manufacturing is restraining the growth of the market. Technological progress in bioprocessing, genetic engineering, and high-throughput screening accelerates the development of novel antibodies, creating opportunities for market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 16.34 billion
Estimated Year [2024] USD 18.04 billion
Forecast Year [2030] USD 33.56 billion
CAGR (%) 10.82%

Antibody Type: Growing need for monoclonal antibodies due to their uniformity, specificity, and large-scale production capabilities

Monoclonal antibodies are identical copies of an antibody that targets a specific antigen. They are produced by a single clone of cells or cell lines and have monovalent affinity, binding only to the same epitope. In the context of contract manufacturing, monoclonal antibodies are generated through sophisticated technologies such as hybridoma development, recombinant DNA, or phage display. These antibodies have a broad range of applications in diagnostics, therapeutics (for diseases such as cancer, autoimmune diseases, and infectious diseases), and research. Their uniformity, specificity, and large-scale production capabilities make them invaluable tools in medicine and biology. Polyclonal antibodies consist of a mixed population of antibody molecules that are produced by different clones of B cells. They recognize and bind to multiple epitopes on a single antigen. Due to this diversity, polyclonal antibodies are often used for detecting a wide range of antigens in immunoprecipitation and immunofluorescence assays. Production involves the immunization of a suitable mammal, such as a rabbit, goat, or mouse, with an antigen. The animal's immune system produces a wide array of antibodies against the antigen, which can then be collected from the serum. Polyclonal antibodies are appreciated for their high sensitivity and ability to capture proteins in their native conformation, but variability from batch to batch is a significant consideration in their production and use.

End-User: Rising adoption of antibodies contract manufacturing among biotechnology & pharmaceutical firms to leverage specialized expertise in antibody production and purification

Academics & research institutions constitute a significant segment of the end-users in the antibodies contract manufacturing market. Utilizing advanced antibody development services for diverse research purposes, these entities focus on understanding disease mechanisms, discovering new therapeutic targets, and developing novel diagnostics tools. The partnership with contract manufacturing organizations (CMOs) allows them to access cutting-edge technologies and expertise without the need for substantial investments in infrastructure, thereby accelerating the pace of scientific discoveries and innovations. Biotechnology & pharmaceutical companies, ranging from startups to well-established firms, heavily rely on antibody contract manufacturing services for various applications, including therapeutic antibody development, diagnostic reagent production, and more. These companies often focus on specific therapeutic areas or novel biotechnological approaches, necessitating the need for specialized, scalable, and cost-effective antibody production solutions. Contract manufacturing partnerships enable biotech companies to navigate the complex regulatory landscapes and manage the risks associated with the biopharmaceutical product development cycle, facilitating a quicker time-to-market for their innovations. The collaboration with CMOs allows pharmaceutical & biotechnology firms to leverage specialized expertise in antibody production and purification, optimize manufacturing processes, and ensure product quality and compliance with global regulatory standards, thus supporting their efforts to deliver safe and effective treatments to patients worldwide.

Regional Insights

The Americas represents a highly developing landscape for the global antibodies contract manufacturing market attributed to the region's robust biopharmaceutical research landscape, significant healthcare spending, and supportive regulatory environment. The US houses several significant contract manufacturing organizations (CMOs) that offer a wide range of services, from early-stage development to large-scale production. Canada and Brazil are also witnessing growth in this sector, though the US continues to lead in terms of market size and technological advancements. The antibody contract manufacturing market in Asia-Pacific is fueled by increasing investment in biotechnology, rising demand for biosimilars, and improving healthcare infrastructure. Countries such as China, South Korea, and India are at the forefront, with their governments implementing favorable policies for biotech advancements. China, in particular, has seen a surge in the establishment of CMOs and contract development and manufacturing organizations (CDMOs) owing to its large patient population and growing biotech industry. The region offers cost-competitive services, which, combined with improving quality standards, makes it an attractive location for outsourcing antibody production. The EMEA region exhibits a strong presence in the antibodies contract manufacturing market, with Europe leading the way due to its highly developed biopharmaceutical sector. Countries including Germany, the United Kingdom, and Switzerland are notable for their sophisticated biotech ecosystems, comprising both established players and emerging biotechs. The presence of stringent regulatory standards ensures high-quality manufacturing processes and outputs. The Middle East and Africa are gradually catching up, with investments in healthcare infrastructure and an increasing focus on biotechnology research.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antibodies Contract Manufacturing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antibodies Contract Manufacturing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antibodies Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include Abeomics, Absolute Antibody by LSBio, Advanced ChemTech, Inc., AGC Biologics, Antibodies, Inc., AstraZeneca, Boehringer Ingelheim Biopharmaceuticals GmbH., Bryllan LLC, Catalent, Inc., CD BioSciences, Charles River Laboratories International, Inc., Eli Lilly and Company, FUJIFILM Holdings Corporation, Fujirebio Inc. by H.U. Group Holdings, Inc., Hycult Biotechnology (H.B.T.) B.V., Labcorp Drug Development, Lonza Group Ltd., Merck KGaA, Molecular Depot LLC, Pierre Fabre S.A, Samsung Biologics, Sapphire Bioscience Pty. Ltd., Scantibodies Laboratory, Inc., Synthon International Holding B.V., The Serum Institute of India, and WuXi Biologics Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Antibodies Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Antibody Type
    • Monoclonal Antibodies
    • Polyclonal Antibodies
  • Source
    • Mammalian
    • Microbial
  • Services
    • Analytical Development & Quality Control
    • Cell Line Development
    • Process Development
  • End-User
    • Academics & Research Institutions
    • Biotechnology & Pharmaceuticals Companies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antibodies Contract Manufacturing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antibodies Contract Manufacturing Market?

3. What are the technology trends and regulatory frameworks in the Antibodies Contract Manufacturing Market?

4. What is the market share of the leading vendors in the Antibodies Contract Manufacturing Market?

5. Which modes and strategic moves are suitable for entering the Antibodies Contract Manufacturing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Development and commercialization need for biopharmaceutical therapeutics
      • 5.1.1.2. Surging need for advanced antibodies for the treatment of chronic diseases
      • 5.1.1.3. Rising preference for personalized medicines
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns regarding development and manufacturing of biologics
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing number of biologics pipelines and growing contract manufacturing service
      • 5.1.3.2. Increasing the R&D budget for the production of antibodies globally
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity of bi/multispecific antibody formats
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Antibody Type: Growing need for monoclonal antibodies due to their uniformity, specificity, and large-scale production capabilities
    • 5.2.2. End-User: Rising adoption of antibodies contract manufacturing among biotechnology & pharmaceutical firms to leverage specialized expertise in antibody production and purification
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Antibodies Contract Manufacturing Market, by Antibody Type

  • 6.1. Introduction
  • 6.2. Monoclonal Antibodies
  • 6.3. Polyclonal Antibodies

7. Antibodies Contract Manufacturing Market, by Source

  • 7.1. Introduction
  • 7.2. Mammalian
  • 7.3. Microbial

8. Antibodies Contract Manufacturing Market, by Services

  • 8.1. Introduction
  • 8.2. Analytical Development & Quality Control
  • 8.3. Cell Line Development
  • 8.4. Process Development

9. Antibodies Contract Manufacturing Market, by End-User

  • 9.1. Introduction
  • 9.2. Academics & Research Institutions
  • 9.3. Biotechnology & Pharmaceuticals Companies

10. Americas Antibodies Contract Manufacturing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Antibodies Contract Manufacturing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Antibodies Contract Manufacturing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Samsung Biologics and LegoChem Biosciences Forge Strategic Alliance to Accelerate ADC Innovation for Solid Tumor Treatment
    • 13.3.2. Aragen Invests USD 30 Million in Bangalore Facility to Boost Biologics Manufacturing Capabilities
    • 13.3.3. KBI Biopharma Unveils SUREmAb, Monoclonal Antibody Development with Accelerated Manufacturing Solutions
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. ANTIBODIES CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTIBODIES CONTRACT MANUFACTURING MARKET DYNAMICS
  • FIGURE 7. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. ANTIBODIES CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. ANTIBODIES CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIBODIES CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY POLYCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY POLYCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MICROBIAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT & QUALITY CONTROL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT & QUALITY CONTROL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ACADEMICS & RESEARCH INSTITUTIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ACADEMICS & RESEARCH INSTITUTIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICALS COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICALS COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 43. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 44. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 45. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 46. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 47. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 48. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 49. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 50. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 51. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 54. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 55. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 56. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 57. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 58. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 59. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 62. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 63. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 64. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 65. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 66. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 67. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 70. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 71. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 72. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 73. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 74. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 75. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 78. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 79. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 80. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 81. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 82. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 98. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 100. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 102. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 103. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 106. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 107. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 108. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 109. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 110. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 111. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 114. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 115. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 116. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 117. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 118. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 119. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 122. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 123. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 124. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 125. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 126. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 127. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 130. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 131. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 132. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 133. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 134. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 135. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 138. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 139. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 140. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 141. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 142. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 143. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 146. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 148. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 150. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 151. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 154. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 155. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 156. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 157. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 158. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 159. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 162. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 164. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 167. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 170. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 171. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 172. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 173. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 174. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 175. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 178. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 179. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 180. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 181. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 182. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 183. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 186. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 187. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 188. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 189. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 190. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 201. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 204. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 205. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 206. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 207. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 208. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 209. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 212. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 213. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 214. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 215. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 216. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 217. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 220. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 221. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 222. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 223. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 224. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 225. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 228. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 229. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 230. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 231. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 232. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 233. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 236. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 237. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 238. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 239. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 240. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 241. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 244. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 245. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 246. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 247. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 248. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 249. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 252. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 253. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 254. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 255. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 256. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 257. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 260. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 262. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 264. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 265. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 268. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 269. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 270. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 271. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 272. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 273. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 276. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 277. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 278. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 279. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 280. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 281. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 284. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 285. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 286. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 287. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 288. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 289. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 292. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 293. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 294. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 295. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 296. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 297. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 298. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 299. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 300. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 301. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 302. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 303. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 304. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 305. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 306. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 307. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 308. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 310. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA ANTI